SUBSCRIBE
SUBSCRIBE
Greg Slabodkin

Greg Slabodkin

Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing. He is an avid Buffalo Bills football fan, likes to kayak and plays guitar.

U.S. Capitol surrounded by money and pill bottles/Taylor Tieden for BioSpace
Editorial
PBMs and Big Pharma Play Blame Game for Inflated Prescription Drug Prices
The Federal Trade Commission criticized the business practices of pharmacy benefit managers this week, but drugmakers are also at fault for the high costs of medicines.
July 12, 2024
 · 
4 min read
 · 
Greg Slabodkin
Podcast
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
Eli Lilly becomes the latest to make a major investment in immunology and inflammation, while antibody-drug conjugate biopharma Myricx Bio nets a large Series A round and new research highlights the potential and possible risks of GLP-1s.
July 10, 2024
 · 
1 min read
 · 
Greg Slabodkin
Podcasts
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
Two CRLs from the FDA last week cited concerns with third-party manufacturers, while Indian CDMOs may make a bid for U.S. business if there is a decoupling from Chinese companies under the BIOSECURE Act.
July 3, 2024
 · 
1 min read
 · 
Jef Akst
Pictured: Blue and white pills on a metal conveyer belt
FDA
FDA Needs to Step Up As Use of Third-Party Manufacturers Leads to Rejections
AbbVie and Merck/Daiichi Sankyo were hit this week with Complete Response Letters from the FDA, which rejected their respective drugs due to manufacturing issues.
June 28, 2024
 · 
3 min read
 · 
Greg Slabodkin
FDA
Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients
While Thursday’s label expansion and traditional approval for the gene therapy is an important milestone, many challenges still face the Duchenne muscular dystrophy community.
June 21, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Abstract visualization of human brain
Drug Development
With Donanemab on the Cusp of Approval, Proper Alzheimer’s Diagnosis Is Urgent
Accurately diagnosing Alzheimer’s disease pathologies is becoming increasingly important, but the U.S. is facing imaging resource constraints.
June 14, 2024
 · 
3 min read
 · 
Greg Slabodkin
Drug Development
MASH Clash Between Lilly and Boehringer-Zealand Takes Center Stage at EASL24
Both Eli Lilly and the partnered companies Boehringer Ingelheim and Zealand Pharma have mid-stage data readouts this week, fueling the race in metabolic dysfunction-associated steatohepatitis.
June 7, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
Securing top talent in research and development and manufacturing will remain challenging for life sciences companies in 2024, according to a new report by CBRE.
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: A collage of biopharma M&A
Deals
Smaller Biopharma M&A on Upswing, Deals Expected to Continue Through 2024
As evidenced by this week’s buyouts by J&J and Merck, Big Pharma appears to have found a sweet spot favoring smaller deals over megabillion-dollar acquisitions.
May 31, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: AstraZeneca with plans to launch 20 new medicines in six years
Business
Is AstraZeneca’s $80B Revenue Goal By 2030 a Bridge Too Far?
CEO Pascal Soriot on Tuesday heralded a “new era of growth” for AstraZeneca with plans to launch 20 new medicines in six years. He’s delivered before but can he do it again?
May 24, 2024
 · 
3 min read
 · 
Greg Slabodkin
Illustration of businessman being erased
Business
Bayer’s 1,500 Layoffs Are Latest Salvo in CEO Bill Anderson’s Company Overhaul
Since taking the helm in 2023, Anderson has embarked on a radical departure from the traditional structure of large pharma companies. Will getting rid of management layers fix Bayer?
May 17, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Panelists on stage at ASGCT (L to R: NHLBI’s Gary Gibbons, NCATS’ Joni Rutter, Amy Jenkins of Advanced Research Projects Agency for Health, NINDS’ Amir Tamiz and ASGCT President Jeffrey Chamberlain)
ASGCT24: Translational Research Powering Potentially Transformative Therapies
Friday’s agenda highlighted some of the pivotal translational studies, as well as the researchers who are making breakthroughs in genetic therapies.
May 10, 2024
 · 
2 min read
 · 
Greg Slabodkin
Pictured: The entrance to the ASGCT meeting at the Baltimore Convention Center
Drug Development
Cell and Gene Therapies Still Have Long Way to Go in Fulfilling Promise
While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how far we are from widespread use.
May 10, 2024
 · 
4 min read
 · 
Greg Slabodkin
Pictured: Speakers sitting on stage at ASGCT 2024; Left to right: Akouos’ Jennifer Wellman, FDA’s Peter Marks, Francielli Melo of Agência Nacional de Vigilância Sanitária and Yoshiaki Maruyama of Japan’s Pharmaceuticals and Medical Devices Agency
Policy
FDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy Oversight
At a Thursday ASGCT 2024 session, CBER Director Peter Marks made the case for a better, “more convergent” global framework on cell and gene therapies, especially for rare diseases.
May 9, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Rare disease ribbon with cut-outs of people
Business
Bespoke Gene Therapy Consortium Targets AAVs for Rare Diseases
Launched in 2021, the public-private consortium on Wednesday updated ASGCT attendees on its efforts to bring adeno-associated virus gene therapies to more rare disease patients.
May 9, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More